SCHEMBL5057148

SCHEMBL5057148

COc1ccc(Cn2c(C)nc3nccc(C(=O)O)c32)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 1/20 0.49
PTGDR2 Q9Y5Y4 1/20 0.47
KDM4E B2RXH2 2/20 0.46
ASPH Q12797 1/20 0.46
KDM8 Q8N371 1/20 0.46
LMNA P02545 2/20 0.46
DCTPP1 Q9H773 3/20 0.44
KDM5A P29375 1/20 0.44
KDM5B Q9UGL1 1/20 0.44
CCR2 P41597 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
ALOX15 P16050 1/20 0.43
CHRM1 P11229 2/20 0.42
USP2 O75604 1/20 0.42
TP53 P04637 1/20 0.42
KLK1 P06870 1/20 0.42
PPARG P37231 2/20 0.41
ADORA3 P0DMS8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1665523 0.90 KDM4E (0.46) PTGDR2KDM4ELMNADCTPP1ALDH1A1
SCHEMBL8601853 0.71 DCTPP1 (0.45) FABP4KDM4EDCTPP1CCR2ALDH1A1
SCHEMBL1667424 0.71 DHODH (0.40) KDM4EASPHKDM8LMNAKDM5A
SCHEMBL2749169 0.71 DCTPP1 (0.60) KDM4ELMNADCTPP1ALDH1A1MAPT
SCHEMBL24476642 0.70 DCTPP1 (0.52) KDM4ELMNADCTPP1ALDH1A1MAPT
SCHEMBL15998969 0.70 NOTUM (0.71) FABP4KDM4ELMNACCR2ALDH1A1
SCHEMBL5052648 0.69 HSP90B1 (0.47) KDM4EASPHKDM8CHRM1
SCHEMBL1271088 0.68 PTGER4 (0.54) FABP4KDM4ELMNAALDH1A1MAPT
SCHEMBL6171067 0.68 DCTPP1 (0.64) KDM4ELMNADCTPP1CCR2ALDH1A1
SCHEMBL16544612 0.67 DCTPP1 (0.56) KDM4ELMNADCTPP1CCR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1912966-A2 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB, S.A. (BE) 2008-04-23 EP claimed
EP-1891042-A2 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB Pharma, S.A. (BE) 2008-02-27 EP claimed
WO-2006128693-A2 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 WO claimed
WO-2006128692-A2 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 WO claimed
EP-1912966-A2 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB, S.A. (BE) 2008-04-23 EP disclosed
EP-1891042-A2 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB Pharma, S.A. (BE) 2008-02-27 EP disclosed
WO-2006128693-A2 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 WO disclosed
WO-2006128692-A2 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 WO disclosed